ORAMED PHARMACEUTICALS INC (ORMP) Institutional Selling Activity

Several institutional investors tracked by InsiderSet reduced exposure to ORAMED PHARMACEUTICALS INC (ORMP) during the quarter ended March 31, 2026 based on sequential SEC Form 13F filings.

The largest disclosed institutional seller of ORMP during the latest reporting period reduced its reported position by approximately $226,250.418 based on quarter-end filing values.

Institutional selling activity may reflect profit-taking, sector rotation, portfolio rebalancing, or changing conviction levels among major investment firms. InsiderSet tracks quarter-over-quarter holding reductions, full exits, estimated value changes, and historical selling activity using publicly disclosed SEC filing data.

The investors covered on this page collectively reduced approximately $254,798.963 in reported ORMP exposure during the latest filing period, although many institutional holders continue to maintain significant long-term ownership positions in ORAMED PHARMACEUTICALS INC.

Portfolio quarterNameTypeQuantityRemainingReported stock balance
Q4 2025Renaissance Technologies LLCSell-1,400147,500$420,375
Q1 2025Renaissance Technologies LLCSell-9,308142,500$304,950
Q4 2024Renaissance Technologies LLCSell-93,492151,808$367,375
Q1 2024Renaissance Technologies LLCSell-218,973122,100$357
Q1 2023Renaissance Technologies LLCSell-347,79711,900$26
Q4 2021Renaissance Technologies LLCSell-169,215203,200$2,902
Q4 2020Renaissance Technologies LLCSell-96,200372,415$1,579
Q1 2020Renaissance Technologies LLCSell-39,310188,415$573
Q3 2018Renaissance Technologies LLCSell-28,95540,845$199
Q1 2018Renaissance Technologies LLCSell-23,70069,800$454

Frequently asked questions about ORMP activity

  • Which institutional owners are buying ORMP?

    Institutional owners buying ORMP include investors who have either initiated new positions or increased their existing holdings based on recent SEC 13F filings. The activity table above highlights which funds added shares in the latest reporting periods and how their positions changed over time.

  • What does "buy" mean in ORMP activity?

    "Buy" means an investor increased their reported position in ORMP compared to the prior reporting period. This reflects growing exposure to ORAMED PHARMACEUTICALS INC (ORMP) rather than necessarily a brand-new position (though new positions also appear as buys when prior quantity was zero).

  • Is institutional interest in ORMP increasing?

    Institutional interest in ORMP can be assessed by comparing the number of tracked funds adding or increasing positions versus those trimming or exiting across the periods shown. A higher number of additions typically signals increasing participation among large filers, but it should be read alongside position sizes and the full table.